• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Dermatology

Autosomal dominant, maternal inheritance of infantile hemangioma

bySara RubinandCordelia Ross
October 12, 2016
in Dermatology, Pediatrics
Reading Time: 3 mins read
Autosomal dominant, maternal inheritance of infantile hemangioma
Share on FacebookShare on Twitter

1. Pedigrees of families with infantile hemangioma (IH) were consistent with 2 distinct modes of transmission: autosomal dominant transmission and maternal inheritance, both with incomplete penetrance.

2. Current discomfort from IH lesions was reported to be greater in familial cases compared to that of sporadic cases.

Study Rundown: Infantile hemangiomas (IHs), also known as “strawberry marks,” are common noncancerous tumors frequently appearing soon after birth. Following a proliferative phase, most hemangiomas shrink and resolve spontaneously over time. However, in rare cases, these vascular anomalies can be fatal (e.g., if they interfere with respiration). Although genetic risk factors for IH, such as mutations in genes involved in angiogenesis, have been reported, much remains to be learned regarding the role of genetics in this disease. To study inheritance and compare familial and sporadic cases of IH, researchers identified index cases from Helsinki University Hospital records and mapped family pedigrees. In some families, pedigree analysis was consistent with an autosomal dominant mode of transmission with incomplete penetrance, while in others the inheritance pattern was more consistent with maternal inheritance with incomplete penetrance. Although no major differences in perinatal risk factors, lesion location, and complications were noted between sporadic and familial cases, current discomfort (at an age range of 7 to 20 years) was reported to be significantly higher among familial cases. A limitation of this study was its lack of in-person examination and reliance on hospital records and questionnaires to identify the study population in addition to its retrospective nature with possible response bias. However, the results strongly support a role for genetics in the pathogenesis of IH and highlight the need for additional research to find the relevant genes. Such information could be useful for clinicians attempting to identify babies, particularly those with low birth weight, who may be at increased risk for developing IH.

Click to read the study, published today in Pediatrics

Relevant Reading: Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants

In-Depth [retrospective cohort]: Electronic health records from the pediatric vascular anomaly clinic at Helsinki University Hospital were used to identify the study sample. Of the 185 children identified with true IH, 136 (74%) responded to a follow-up questionnaire assessing IH family history, perinatal information, and present IH-related discomfort (on a visual analog scale from 1 to 10). The individuals with a positive family history (i.e., those with ≥1 relative with IH) were interviewed by phone. This data was then used to construct 40 pedigrees for mode of inheritance and founder effect analysis. Two modes of inheritance, both with incomplete penetrance, were identified: autosomal dominant transmission and maternal inheritance. A founder effect was not observed. Due to the low number of twins in the study, it was not possible to perform a statistical assessment of concordance. However, of note was the identification of concordant monozygotic twins with IH lesions in the same location. As for a comparison of familial and sporadic IH cases, no significant differences were found, except that the current mean discomfort rate (as assessed by questionnaire at a mean age 10.1 years, range 7-20 years) for index cases and their IH-affected first-degree relatives was higher than that of sporadic cases (p = 0.036).

RELATED REPORTS

One in three people with cystic fibrosis may experience nephrolithiasis during their life

Australian couple-based genetic screening program feasible and accepted

Genomic sequencing identifies variants linked to congenital diarrhea and enteropathies

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: geneticshemangioma
Previous Post

Colorectal cancer prevention though screening colonoscopies may have less benefit in those older than 75

Next Post

New imaging technology can visualize cancer cells in patients [PreClinical]

RelatedReports

Contrast-enhanced computed tomography associated with high sensitivity to renal stone detection
Chronic Disease

One in three people with cystic fibrosis may experience nephrolithiasis during their life

January 15, 2026
Parents desensitized with increasing exposure to movie violence/sex
Public Health

Australian couple-based genetic screening program feasible and accepted

August 27, 2025
Non-invasive prenatal testing linked to decreased diagnostic testing
Chronic Disease

Genomic sequencing identifies variants linked to congenital diarrhea and enteropathies

April 11, 2025
Maternal cell-free DNA sequencing superior to standard aneuploidy screening [CARE Study]
Career Development

Australian couple-based genetic screening program feasible and accepted

December 11, 2024
Next Post
High incidence of foreskin morbidity in uncircumcised males

New imaging technology can visualize cancer cells in patients [PreClinical]

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Spiculation of breast masses seen on mammography represents adipose invasion

Advent of mammography associated with increased detection of smaller breast tumors

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transanastomotic tubes not linked to anastomotic stricture after esophageal atresia repair
  • Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms
  • Real-time AI guidance enters live brain tumor surgery
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.